Kübra Karagoz

985 total citations
25 papers, 685 citations indexed

About

Kübra Karagoz is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Kübra Karagoz has authored 25 papers receiving a total of 685 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 7 papers in Cancer Research and 5 papers in Oncology. Recurrent topics in Kübra Karagoz's work include Bioinformatics and Genomic Networks (5 papers), MicroRNA in disease regulation (5 papers) and Computational Drug Discovery Methods (4 papers). Kübra Karagoz is often cited by papers focused on Bioinformatics and Genomic Networks (5 papers), MicroRNA in disease regulation (5 papers) and Computational Drug Discovery Methods (4 papers). Kübra Karagoz collaborates with scholars based in United States, Türkiye and United Kingdom. Kübra Karagoz's co-authors include Kazım Yalçın Arğa, Raghu Sinha, Michael L. Gatza, Beste Turanlı, Adil Mardinoğlu, Recep Bayraktar, Pınar Kanlikilicer, Esra Göv, Nermin Kahraman and Elif Kılıç and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Cancer Research.

In The Last Decade

Kübra Karagoz

24 papers receiving 682 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kübra Karagoz United States 14 496 250 117 69 60 25 685
Aparna Gorthi United States 13 548 1.1× 129 0.5× 147 1.3× 33 0.5× 99 1.6× 23 754
Laoighse Mulrane Ireland 9 501 1.0× 351 1.4× 142 1.2× 34 0.5× 94 1.6× 15 777
Heather M. Selby United States 14 428 0.9× 152 0.6× 265 2.3× 35 0.5× 72 1.2× 24 666
Reid T. Powell United States 12 604 1.2× 174 0.7× 157 1.3× 48 0.7× 81 1.4× 38 949
Aritro Nath United States 15 640 1.3× 477 1.9× 186 1.6× 78 1.1× 94 1.6× 37 957
Beste Turanlı Türkiye 16 500 1.0× 141 0.6× 107 0.9× 58 0.8× 138 2.3× 33 737
Emmanuel Petricoin United States 11 597 1.2× 146 0.6× 146 1.2× 57 0.8× 74 1.2× 19 871
Nicolas Borisov Russia 18 404 0.8× 182 0.7× 96 0.8× 28 0.4× 128 2.1× 31 659
Khadijeh Barzaman Iran 7 384 0.8× 236 0.9× 256 2.2× 118 1.7× 134 2.2× 8 769
Shiva Krupa United States 3 986 2.0× 220 0.9× 147 1.3× 76 1.1× 113 1.9× 4 1.2k

Countries citing papers authored by Kübra Karagoz

Since Specialization
Citations

This map shows the geographic impact of Kübra Karagoz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kübra Karagoz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kübra Karagoz more than expected).

Fields of papers citing papers by Kübra Karagoz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kübra Karagoz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kübra Karagoz. The network helps show where Kübra Karagoz may publish in the future.

Co-authorship network of co-authors of Kübra Karagoz

This figure shows the co-authorship network connecting the top 25 collaborators of Kübra Karagoz. A scholar is included among the top collaborators of Kübra Karagoz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kübra Karagoz. Kübra Karagoz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Brody, Joshua, Judit Jørgensen, David Belada, et al.. (2025). Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial. Blood. 145(15). 1621–1631. 12 indexed citations
2.
Jackson, Stephanie R., et al.. (2024). Mechanisms of extracellular vesicle uptake and implications for the design of cancer therapeutics. SHILAP Revista de lepidopterología. 3(11). e70017–e70017. 6 indexed citations
3.
Soong, David S., Sriram Sridhar, Christina Y. Yu, et al.. (2024). Improving accuracy of GPT-3/4 results on biomedical data using a retrieval-augmented language model. PLOS Digital Health. 3(8). e0000568–e0000568. 19 indexed citations
4.
5.
Karagoz, Kübra, Lauren Brady, Brandon W. Higgs, & Han Si. (2024). Abstract 6206: Molecular stratification of AML: Integrative genomic and immune profiling points to high risk subgroup and targetable molecular drivers. Cancer Research. 84(6_Supplement). 6206–6206. 1 indexed citations
6.
Gooding, Sarah, Naser Ansari‐Pour, Kübra Karagoz, et al.. (2022). Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma. Blood. 140(16). 1816–1821. 13 indexed citations
7.
Karagoz, Kübra, Matthew P. Stokes, Fadi Towfic, et al.. (2022). Multiple Myeloma Patient Tumors With High Levels of Cereblon Exon-10 Deletion Splice Variant Upregulate Clinically Targetable Pro-Inflammatory Cytokine Pathways. Frontiers in Genetics. 13. 831779–831779. 3 indexed citations
8.
Gooding, Sarah, Naser Ansari‐Pour, Kübra Karagoz, et al.. (2021). Loss of COP9 Signalosome Gene-Containing 2q Region Is Associated with Lenalidomide and Pomalidomide Resistance in Myeloma Patients. Blood. 138(Supplement 1). 458–458.
9.
Omene, Coral, Lin Ma, Haoxu Ouyang, et al.. (2019). Aggressive Mammary Cancers Lacking Lymphocytic Infiltration Arise in Irradiated Mice and Can Be Prevented by Dietary Intervention. Cancer Immunology Research. 8(2). 217–229. 11 indexed citations
10.
11.
Turanlı, Beste, Kübra Karagoz, Gizem Gülfidan, et al.. (2019). A Network-Based Cancer Drug Discovery: From Integrated Multi-Omics Approaches to Precision Medicine. Current Pharmaceutical Design. 24(32). 3778–3790. 52 indexed citations
12.
Turanlı, Beste, Kübra Karagoz, Gholamreza Bidkhori, et al.. (2019). Multi-Omic Data Interpretation to Repurpose Subtype Specific Drug Candidates for Breast Cancer. Frontiers in Genetics. 10. 420–420. 36 indexed citations
13.
Kanlikilicer, Pınar, Recep Bayraktar, Merve Denizli, et al.. (2018). Exosomal Mirna Confers Chemo Resistance Via Targeting Cav1/p-gp/M2-Type Macrophage Axis in Ovarian Cancer. SSRN Electronic Journal. 2 indexed citations
14.
Mokhlis, Hamada A., Recep Bayraktar, Nashwa Kabil, et al.. (2018). The Modulatory Role of MicroRNA-873 in the Progression of KRAS-Driven Cancers. Molecular Therapy — Nucleic Acids. 14. 301–317. 28 indexed citations
15.
Kanlikilicer, Pınar, Recep Bayraktar, Merve Denizli, et al.. (2018). Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer. EBioMedicine. 38. 100–112. 185 indexed citations
16.
Qi, Xin, Kübra Karagoz, Jian Ren, David J. Foran, & Michael L. Gatza. (2018). Differentiation among prostate cancer patients with Gleason score of 7 using histopathology image and genomic data. PubMed. 66. 1–1. 9 indexed citations
17.
Brighton, Hailey E., Steven P. Angus, Tao Bo, et al.. (2017). New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging. Cancer Research. 78(2). 542–557. 57 indexed citations
18.
Sinha, Indu, Kübra Karagoz, Christopher S. Hollenbeak, et al.. (2016). “Omics” of Selenium Biology: A Prospective Study of Plasma Proteome Network Before and After Selenized-Yeast Supplementation in Healthy Men. OMICS A Journal of Integrative Biology. 20(4). 202–213. 22 indexed citations
19.
Karagoz, Kübra, et al.. (2016). Integration of multiple biological features yields high confidence human protein interactome. Journal of Theoretical Biology. 403. 85–96. 21 indexed citations
20.
Karagoz, Kübra & Kazım Yalçın Arğa. (2013). Assessment of high-confidence protein–protein interactome in yeast. Computational Biology and Chemistry. 45. 1–8. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Aparna Gorthi Breakdown of academic impact, for papers by Laoighse Mulrane Breakdown of academic impact, for papers by Heather M. Selby Breakdown of academic impact, for papers by Reid T. Powell Breakdown of academic impact, for papers by Aritro Nath Breakdown of academic impact, for papers by Beste Turanlı Breakdown of academic impact, for papers by Emmanuel Petricoin Breakdown of academic impact, for papers by Nicolas Borisov Breakdown of academic impact, for papers by Khadijeh Barzaman Breakdown of academic impact, for papers by Shiva Krupa
Rankless by CCL
2026